Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher
11 November 2024 - 7:46PM
AllPennyStocks.com
This late-stage clinical trial company focuses on preventing
inflammation and acute organ injury. It is developing a platform of
new drugs to prevent inflammation in the kidneys, liver and
lungs...
To read the full story on AllPennyStocks.com, click
here.
Arch Biopartners (TSXV:ARCH)
Historical Stock Chart
Von Feb 2025 bis Mär 2025
Arch Biopartners (TSXV:ARCH)
Historical Stock Chart
Von Mär 2024 bis Mär 2025